9/4/2019 7:05:34 AM
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7/3/2019 7:35:19 AM
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7/1/2019 7:43:03 AM
BioCryst Pharma Appoints Megan Sniecinski As Chief Business Officer
5/21/2019 7:07:36 AM
BioCryst Says Oral BCX7353 Meets Primary Endpoint In Phase 3 APeX-2 Trial
5/6/2019 7:08:35 AM
BioCryst Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/4/2019 7:13:10 AM
BioCryst Q4 Net Loss $27.4 Mln Or $0.25/Shr Vs Loss Of $19.5 Mln Or $0.20/Shr Last Year
1/4/2019 7:02:19 AM
BioCryst Appoints Steve Aselage To Board Of Directors
1/2/2019 7:04:47 AM
BioCryst Begins Phase 1 Clinical Trial Of Galidesivir
11/16/2018 7:07:48 AM
BioCryst Presents Data Highlighting Rapid And Sustained Plasma Concentrations Of BCX7353 In HAE Patients At ACAAI
11/6/2018 7:11:36 AM
BioCryst Pharma Q3 Net Loss $29.6 Mln Or $0.28/Shr Vs Loss Of $15.1 Mln Or $0.18/Shr Last Year
9/6/2018 7:10:25 AM
CDC Awards BioCryst $35 Mln RAPIVAB Contract For Strategic National Stockpile
9/4/2018 7:09:33 AM
BioCryst Reports Initial Results From ZENITH-1 Trial Showing Single 750 Mg Oral Dose Of BCX7353 Was Well Tolerated
8/7/2018 6:06:21 AM
BioCryst Pharma Q2 Net Loss $18.5 Mln Or $0.19/shr Vs. Net Loss $16.9 Mln Or $0.21/shr Last Year
8/6/2018 6:02:55 AM
BioCryst Says US FDA Grants Fast Track Designation For BCX7353 For Prevention Of Angioedema Attacks In Patients With HAE